XOMA
XOMA Royalty is a biotech royalty aggregator that plays a unique role in helping biotech companies achieve their goal of improving human health. They do this by acquiring the economic rights to future milestone and royalty payments associated with partnered pre-commercial clinical candidates. The company focuses on building a diversified portfolio of over 70 assets, providing non-dilutive, non-recourse funding to biotech companies, and operates under a capital-efficient structure. Their strategy involves acquiring rights to future payments, supporting the development of therapeutic assets, and generating value for shareholders through royalty and milestone revenues.
Industries
Nr. of Employees
medium (51-250)
Products
Aggregated portfolio of milestone and royalty rights
A managed collection of contractual rights to milestone payments and royalties tied to a broad set of therapeutic candidates and commercial therapies across multiple stages of development and therapeutic areas.
AB023
A royalty-backed biopharmaceutical asset or clinical program associated with Xisomab 3G3.
OHB-607
A clinical efficacy and safety study of OHB-607 in preventing bronchopulmonary dysplasia in extremely premature infants.
Volixibat
Volixibat is a royalty interest and investigational therapeutic product being evaluated across various conditions such as intrahepatic cholestasis of pregnancy, primary sclerosing cholangitis, and NASH.
MIPLYFFA
MIPLYFFA (arimoclomol) is a therapeutic product subject to royalty investments and clinical studies for conditions such as Niemann-Pick disease Type C.
Seralutinib
A royalty-backed biopharmaceutical asset evaluated in clinical studies for pulmonary arterial hypertension and related conditions.
Aggregated portfolio of milestone and royalty rights
A managed collection of contractual rights to milestone payments and royalties tied to a broad set of therapeutic candidates and commercial therapies across multiple stages of development and therapeutic areas.
AB023
A royalty-backed biopharmaceutical asset or clinical program associated with Xisomab 3G3.
OHB-607
A clinical efficacy and safety study of OHB-607 in preventing bronchopulmonary dysplasia in extremely premature infants.
Volixibat
Volixibat is a royalty interest and investigational therapeutic product being evaluated across various conditions such as intrahepatic cholestasis of pregnancy, primary sclerosing cholangitis, and NASH.
MIPLYFFA
MIPLYFFA (arimoclomol) is a therapeutic product subject to royalty investments and clinical studies for conditions such as Niemann-Pick disease Type C.
Seralutinib
A royalty-backed biopharmaceutical asset evaluated in clinical studies for pulmonary arterial hypertension and related conditions.
Services
Acquiring contractual rights to future milestone and royalty payments on therapeutic assets in exchange for non-dilutive, non-recourse capital to the seller.
Offering select acquired royalty and milestone interests or development-stage assets for licensing or further monetization by third parties.
Ongoing management of an aggregated portfolio of royalty and milestone interests, including reinvestment of milestone proceeds and tactical capital deployment to expand the portfolio.
Acquiring contractual rights to future milestone and royalty payments on therapeutic assets in exchange for non-dilutive, non-recourse capital to the seller.
Offering select acquired royalty and milestone interests or development-stage assets for licensing or further monetization by third parties.
Ongoing management of an aggregated portfolio of royalty and milestone interests, including reinvestment of milestone proceeds and tactical capital deployment to expand the portfolio.
Expertise Areas
- Royalty acquisition and monetization
- Portfolio management of milestone and royalty interests
- Deal structuring and capital deployment for biotech assets
- Clinical-stage asset evaluation and diligence
Key Technologies
- Phage display and antibody discovery platforms
- Royalty-backed financing structures
- Portfolio aggregation of milestone and royalty rights
- Clinical development stage assessment
News & Updates
XOMA entered into a non-dilutive, non-recourse, royalty-backed loan for up to $140 million of capital with funds managed by Blue Owl Capital Inc., backed by VABYSMO® royalties.
The European Commission granted approval for VABYSMO® (faricimab-svoa), Roche’s bispecific antibody for the treatment of nAMD and DME, marking XOMA’s first portfolio asset to receive FDA approval.
XOMA entered into a non-dilutive, non-recourse, royalty-backed loan for up to $140 million of capital with funds managed by Blue Owl Capital Inc., backed by VABYSMO® royalties.
The European Commission granted approval for VABYSMO® (faricimab-svoa), Roche’s bispecific antibody for the treatment of nAMD and DME, marking XOMA’s first portfolio asset to receive FDA approval.